

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

07 AUG 14 PM 1:26

SECRETARY OF THE SENATE

LOBBYING PREP

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization Individual

Novartis Vaccines and Diagnostics, Inc.

2. Address Check if different than previously reported

Address1 701 Pennsylvania Avenue, Suite 725 Address2
City Washington State DC Zip Code 20004 Count

3. Principal place of business (if different than line 2)

City Washington State DC Zip Code 20004 Count

4a. Contact Name Mrs. Marguerite D. Baxter
b. Telephone Number (202) 626-0100
c. E-mail marguerite.baxter@novartis.com
5. Senat 31169

7. Client Name Self
Novartis Vaccines and Diagnostics, Inc.
6. Hous 38543

TYPE OF REPORT 8. Year 2007 Midyear (January1-June30) Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more \$

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more \$ 265,000.00

14. REPORTING Check box to indicate accounting method. See instructions for description

- Method A. Reporting amounts using LDA definition
- Method B. Reporting amounts under section 6033(b) Internal Revenue Code
- Method C. Reporting amounts under section 162(e) Revenue Code

Signature Digitally Signed By: Marguerite Baxter Date 08/13

US, DST ACES Business Representative, CHIRON CORPORATION, Marguerite Baxter

Printed Name and Title Marguerite Baxter, Vice President and Head, Global Public Affairs

0000073999

Registrant Novartis Vaccines and Diagnostics, Inc. Client Name Novartis Vaccines and Diagnostics, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code (one per page)

16. Specific lobbying issues
 S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, pandemic influenza and vaccine issues
 H.R. 3043, Labor-HHS-Education and Related Agencies Appropriations Act, pandemic influenza and vaccine issues
 H.J. Res. 20, Revised Continuing Appropriations Resolution, pandemic influenza funding

17. House(s) of Congress and Federal agencies Check if None House Senate
 Centers for Disease Control and Prevention
 Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

| Name | | | Covered Official Position (if applicable) |
|------------|--------|--------|---|
| First | Last | Suffix | |
| Marguerite | Baxter | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

19. Interest of each foreign entry in the specific issues listed on line 16 above Check if None

3000074000

Printed Name and Title **Marguerite Baxter, Vice President and Head, Global Public Affairs**

ADDENDUM for General Lobbying Issue Area: BUD - Budget/Appropriations

H.R. 1591, Emergency Supplemental Appropriations, pandemic influenza funding

Hr.R. 2638, Homeland Security Appropriations Act, pandemic influenza

S. 1644, Homeland Security Appropriations Act, pandemic influenza

S. 965, U.S. Troop Readiness, Veterans' Care, Katrina Recovery and Iraq Accountability Appropriations Act, 2007, pandemic influenza funding

H.R. 2206, U.S. Troop Readiness, Veterans' Care, Kartina Recovery and Iraq Accountability Appropriations Act, 2007, pandemic influenza funding

0000074001

Printed Name and Title Marguerite Baxter, Vice President and Head, Global Public Affairs

Registrant Novartis Vaccines and Diagnostics, Inc. Client Name Novartis Vaccines and Diagnostics, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR Health Issues (one per page)

16. Specific lobbying issues

H.R. 1973, Vaccine Safety and Public Confidence Assurance Act of 2007, vaccine tracking issues
 H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007, PDUFA, drug safety provisions
 S. 1082, Prescription Drug User Fee Amendments of 2007, PDUFA, drug safety provisions

17. House(s) of Congress and Federal agencies Check if None House Senate

Centers for Disease Control and Prevention
 Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

| Name | | | Covered Official Position (if applicable) |
|------------|--------|--------|---|
| First | Last | Suffix | |
| Marguerite | Baxter | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000074002

Printed Name and Title Marguerite Baxter, Vice President and Head, Global Public Affairs

ADDENDUM for General Lobbying Issue Area: HCR - Health Issues

- H.R. 2900, Food and Drug Administration Amendments Act of 2007, PDUFA, Drug Safety provisions
- S. 467, FACT Act, clinical trials/drug safety provisions
- S. 596, Enhancing Drug Safety and Innovation Act of 2007, clinical trials/drug safety provisions
- S. 993, Pediatric Research Improvement Act, clinical trials/drug safety provisions

0000074003

Printed Name and Title **Marguerite Baxter, Vice President and Head, Global Public Affairs**

Registrant Novartis Vaccines and Diagnostics, Inc. Client Name Novartis Vaccines and Diagnostics, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code

| | |
|-----|-------|
| TOR | Torts |
|-----|-------|

 (one per page)

16. Specific lobbying issues

H.J. Res. 20, Revised Continuing Appropriations Resolution, pandemic liability language
 Department of Defense Appropriations, pandemic liability language

17. House(s) of Congress and Federal agencies Check if None House Senate

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

| Name | | | Covered Official Position (if applicable) |
|------------|--------|--------|---|
| First | Last | Suffix | |
| Marguerite | Baxter | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000074004

Printed Name and Title **Marguerite Baxter, Vice President and Head, Global Public Affairs**

Registrant Novartis Vaccines und Diagnostics, Inc.

Client Name Novartis Vaccines und Diagnostics, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code (one per page)

16. Specific lobbying issues

S. 1145, Patent Reform Act of 2007, entire bill
H.R. 1908, Patent Reform Act of 2007, entire bill

17. House(s) of Congress and Federal agencies Check if None House Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | | | Covered Official Position (if applicable) |
|------------|--------|--------|---|
| First | Last | Suffix | |
| Marguerite | Baxter | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

3000074005

Printed Name and Title **Marguerite Baxter, Vice President and Head, Global Public Affairs**

Registrant Novartis Vaccines and Diagnostics, Inc. Client Name Novartis Vaccines and Diagnostics, Inc.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address 701 Pennsylvania Avenue, Suite 725

City Washington State DC Zip Code 20004 - Court

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ - Court

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expect to act as a lobbyist for the client

| | First Name | Last Name | Suffix | City/State | Zip Code |
|---|------------|-----------|--------|------------|----------|
| 1 | | | | | 3 |
| 2 | | | | | 4 |

ISSUE UPDATE

24. General lobbying issue that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

| Name | Address | | | | Principal Place of Business (city and state or country) | |
|------|----------------|----------------|-----|---------|---|---------|
| | Street Address | State/Province | Zip | Country | City | Country |
| | City | | | | State | Country |
| | | | | | City | Country |
| | | | | | State | Country |

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

| | | |
|---|---|---|
| 1 | 2 | 3 |
|---|---|---|

FOREIGN ENTITIES

27. Add the following foreign entities

| Name | Address | | | Principal place of business (city and state or country) | Amount of contribution for lobbying activities |
|-------------|--------------------|----------------|---------|---|--|
| | Street Address | State/Province | Country | | |
| Novartis AG | Lichstrasse 35 WSI | | SUI | City State Country | \$0.00 |
| | Basel | | | | |

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated org

| | | |
|---|---|---|
| 1 | 3 | 5 |
| 2 | 4 | 6 |

000074006

Printed Name and Title Marguerite Baxter, Vice President and Head, Global Public Affairs

